文献速递慢性肾脏病血液净化与透析

司美格鲁肽对COVID-19及其他感染的影响:FLOW随机临床试验分析

Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trial.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

FLOW试验预设分析评估司美格鲁肽1.0mg皮下 weekly 对T2D合并CKD患者感染风险的影响。

要点

  • 司美格鲁肽降低感染SAE、感染住院及全因死亡复合终点风险。
  • 基线HbA1c>8%或UACR≥2000mg/g者获益更显著。
  • COVID-19相关SAE和不良事件发生率亦降低。

核心结论

  • 司美格鲁肽降低T2D合并CKD患者感染SAE、感染住院及全因死亡风险。
  • 血糖控制差和基线白蛋白尿高的患者获益更大。

研究设计与样本

  • FLOW试验(NCT03819153)预设分析,每周一次皮下司美格鲁肽1.0mg对比安慰剂。
  • 研究对象为2型糖尿病合并慢性肾脏病患者。

临床怎么用

  • 对T2D合并CKD高危患者,司美格鲁肽可能降低感染相关住院和死亡风险。
  • 血糖控制差或白蛋白尿高的患者可能优先获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the FLOW trial (Evaluate Renal Function with Semaglutide Once-Weekly; ClinicalTrials.gov, NCT03819153), once-weekly subcutaneous semaglutide 1.0 mg versus placebo reduced the risk of major kidney, cardiovascular (CV) and mortality outcomes in participants with type 2 diabetes (T2D) and chronic kidney disease (CKD). This pre-specified analysis assesses the impact of semaglutide on risks of serious infections and coronavirus disease 2019 (COVID-19) in the FLOW trial. METHODS: The main outcome was a three-component composite [time from randomization to first infection serious adverse event (SAE), first hospitalization due to infection, or all-cause death]. Other outcomes included all infection SAEs, COVID-19 adverse events, COVID-19 SAEs, death due to infection and death concurrent with a COVID-19 SAE. RESULTS: Semaglutide reduced the risk of the main outcome versus placebo [hazard ratio (HR) (95% confidence interval) 0.79 (0.69-0.89); P = .0002]. This risk reduction was greater in subgroups with baseline hemoglobin A1c >8% [HR 0.63 (0.52-0.76)] versus ≤8% [HR 0.93 (0.79-1.11); Pinteraction = .0027], and urine albumin-to-creatinine ratio (UACR) ≥2000 mg/g [HR 0.53 (0.39-0.72)] versus UACR <100 mg/g [HR 0.90 (0.58-1.39); Pinteraction = .0367]. The semaglutide group had a lower rate of infection SAEs (17.9% versus 21.3%; P = .0070), COVID-19 SAEs (6.7% versus 8.8%; P = .0155), COVID-19 adverse events (20.3% versus 22.9%; P = .0190) and hospitalization due to infection (17.5% versus 20.4%; P = .015). CONCLUSIONS: Semaglutide reduced risks of infection SAEs, hospitalization due to infection, and all-cause death with greater benefit among those with poorer glycemic control and greater baseline albuminuria. These findings support potential clinical benefits of semaglutide beyond kidney, CV and metabolic outcomes in high-risk patients with T2D and CKD.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Rayner B, Mahaffey KW, Mann JFE, et al. Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trial. Nephrol Dial Transplant. 2026. PMID: 41728915. doi:10.1093/ndt/gfag036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。